Get The App!
Loading the player...
Survival Benefit of Ruxolitinib to Best Available Therapy – COMFORT II Trial
Share by Email
Send to social websites
Report this video as inappropriate
You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email.
Select your reason
Violent or Repulsive Content
Hateful or Abusive Content
Harmful Dangerous Acts
John Mascarenhas, M.D., Assistant Professor Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine
New Therapies in Treating MPNs
Discussion on Disease Modifying Therapies
Discussion on QOL Issues
What do Pharmacists Need to Know
Interruption of Therapy with Ruxolitinib
Treatment Issues for First Time Patients on Ruxolitinib
Platelet Count and Proper Dosing of Ruxolitinib in New Patients
Titration with Ruxolitinib – Titrate up or down?
Copyright 2020 by NSCI Group, Inc.
On The Go
About MedEd On The Go